Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration - PubMed (original) (raw)
Review
doi: 10.1016/j.neuroscience.2005.07.060. Epub 2005 Dec 5.
P A Serra, F L'episcopo, C Tirolo, S Caniglia, N Testa, F Gennuso, G Giaquinta, G Rocchitta, M S Desole, E Miele, B Marchetti
Affiliations
- PMID: 16337092
- DOI: 10.1016/j.neuroscience.2005.07.060
Review
Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration
M C Morale et al. Neuroscience. 2006.
Abstract
Post-menopausal estrogen deficiency is recognized to play a pivotal role in the pathogenesis of a number of age-related diseases in women, such as osteoporosis, coronary heart disease and Alzheimer's disease. There are also sexual differences in the progression of diseases associated with the nigrostriatal dopaminergic system, such as Parkinson's disease, a chronic progressive degenerative disorder characterized by the selective degeneration of mesencephalic dopaminergic neurons in the substancia nigra pars compacta. The mechanism(s) responsible for dopaminergic neuron degeneration in Parkinson's disease are still unknown, but oxidative stress and neuroinflammation are believed to play a key role in nigrostriatal dopaminergic neuron demise. Estrogen neuroprotective effects have been widely reported in a number of neuronal cell systems including the nigrostriatal dopaminergic neurons, via both genomic and non-genomic effects, however, little is known on estrogen modulation of astrocyte and microglia function in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. We here highlight estrogen modulation of glial neuroinflammatory reaction in the protection of mesencephalic dopaminergic neurons and emphasize the cardinal role of glia-neuron crosstalk in directing neuroprotection vs neurodegeneration. In particular, the specific role of astroglia and its pro-/anti-inflammatory mechanisms in estrogen neuroprotection are presented. This study shows that astrocyte and microglia response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injury vary according to the estrogenic status with direct consequences for dopaminergic neuron survival, recovery and repair. These findings provide a new insight into the protective action of estrogen that may possibly contribute to the development of novel therapeutic treatment strategies for Parkinson's disease.
Similar articles
- Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC. Marchetti B, et al. Ann N Y Acad Sci. 2005 Dec;1057:296-318. doi: 10.1196/annals.1356.023. Ann N Y Acad Sci. 2005. PMID: 16399902 Review. - Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions.
Marchetti B, Serra PA, Tirolo C, L'episcopo F, Caniglia S, Gennuso F, Testa N, Miele E, Desole S, Barden N, Morale MC. Marchetti B, et al. Brain Res Brain Res Rev. 2005 Apr;48(2):302-21. doi: 10.1016/j.brainresrev.2004.12.030. Brain Res Brain Res Rev. 2005. PMID: 15850669 Review. - Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
Tripanichkul W, Sripanichkulchai K, Finkelstein DI. Tripanichkul W, et al. Brain Res. 2006 Apr 21;1084(1):28-37. doi: 10.1016/j.brainres.2006.02.029. Epub 2006 Mar 27. Brain Res. 2006. PMID: 16564034 - Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybyłkowski A, Członkowski A, Członkowska A. Kurkowska-Jastrzebska I, et al. Int Immunopharmacol. 2004 Oct;4(10-11):1307-18. doi: 10.1016/j.intimp.2004.05.006. Int Immunopharmacol. 2004. PMID: 15313429
Cited by
- Dysregulation of a Heme Oxygenase-Synuclein Axis in Parkinson Disease.
Cressatti M, Schipper HM. Cressatti M, et al. NeuroSci. 2022 May 20;3(2):284-299. doi: 10.3390/neurosci3020020. eCollection 2022 Jun. NeuroSci. 2022. PMID: 39483365 Free PMC article. Review. - Negative association of serum neurofilament light chain with estimated glomerular filtration rate levels and the impact of gender.
Peng H, Liang Z, Huang B, Zhang S, Yang Y. Peng H, et al. Front Neurol. 2024 Sep 11;15:1457984. doi: 10.3389/fneur.2024.1457984. eCollection 2024. Front Neurol. 2024. PMID: 39323436 Free PMC article. - Astrocyte-derived apolipoprotein D is required for neuronal survival in Parkinson's disease.
Dai Y, Bi M, Jiao Q, Du X, Yan C, Jiang H. Dai Y, et al. NPJ Parkinsons Dis. 2024 Aug 2;10(1):143. doi: 10.1038/s41531-024-00753-8. NPJ Parkinsons Dis. 2024. PMID: 39095480 Free PMC article. - Role of Epigenetic Modulation in Neurodegenerative Diseases: Implications of Phytochemical Interventions.
Prasanth MI, Sivamaruthi BS, Cheong CSY, Verma K, Tencomnao T, Brimson JM, Prasansuklab A. Prasanth MI, et al. Antioxidants (Basel). 2024 May 15;13(5):606. doi: 10.3390/antiox13050606. Antioxidants (Basel). 2024. PMID: 38790711 Free PMC article. Review. - The identification of c-Abl inhibitors as potential agents for Parkinson's disease: a preliminary in silico approach.
Rymbai E, Roy D, Jupudi S, Srinivasadesikan V. Rymbai E, et al. Mol Divers. 2024 Dec;28(6):4051-4065. doi: 10.1007/s11030-023-10796-3. Epub 2024 Jan 25. Mol Divers. 2024. PMID: 38273156
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous